Transaktion:
Budpliktsbud
Period:
–
Toleranzia AB
Toleranzia develops drugs that use the immune system’s own intrinsic power to treat autoimmune orphan diseases. The drugs, which target the cause of the disease, can cure or greatly alleviate the disease and not, like current treatments, only reduce the symptoms. They have the potential to become the first long-acting or curative treatments that act specifically on the underlying cause of the autoimmune orphan disease they are developed for.
Sammanfattning
Acceptperiod: 16 november – 14 december 2022
Vederlag: 1,02 kronor per aktie
Beräknad likvidag: omkring 21 december 2022